Home › Trial NCT04439188
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)
- Trial IDNCT04439188
- StatusActive Not Recruiting
- PhasePhase 2
- Study typeInterventional
- SponsorNational Cancer Institute (NCI)
- Enrollment35
- Start date2016-03-21
- ConditionsAdvanced Lymphoma · Advanced Malignant Solid Neoplasm · Hematopoietic and Lymphoid Cell Neoplasm · Refractory Lymphoma · Refractory Malignant Solid Neoplasm · Refractory Multiple Myeloma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.